A multidimensional tool to quantify treatment resistance in depression: the Maudsley staging method
- PMID: 19192471
- DOI: 10.4088/jcp.08m04309
A multidimensional tool to quantify treatment resistance in depression: the Maudsley staging method
Abstract
Objective: Treatment resistance is a common clinical phenomenon in depression. However, current unitary models of staging fail to represent its complexity. We aimed to devise a model to stage treatment-resistant depression, taking into account the core factors contributing to treatment failure.
Method: We reviewed the literature to identify factors consistently associated with treatment resistance. We also analyzed data from a subgroup of patients discharged from a specialist inpatient unit for whom adequate data were obtainable.
Results: We present a points-based staging model incorporating 3 factors: treatment, severity of illness, and duration of presenting episode. In this model, the rating of symptom severity ranges from subsyndromal depression (score 1) to severe syndromal depression with psychosis (score 5). Antidepressant treatment is rated on a 5-point subscale based on number of medications used, while duration of the presenting episode is rated on a 3-point subscale. The overall level of resistance estimated using this model varies from minimal resistance (score of 3) to severe resistance (score of 15). The rating system allows the overall severity of treatment resistance to be summarized either as a single numeric score or under a single descriptive category. It may also be possible to specify categories (mild, moderate, and severe) based on severity of resistance. Analysis of inpatient data indicates that the factors incorporated in the model and the model itself have some predictive validity.
Conclusion: This staging model has reasonable face and predictive validity and may have better utility in staging treatment resistance than currently available methods.
Copyright 2009 Physicians Postgraduate Press, Inc.
Comment in
-
Pseudoresistant bipolar depression.J Clin Psychiatry. 2009 Oct;70(10):1476-7; author reply 1477. doi: 10.4088/JCP.09lr05181gre. J Clin Psychiatry. 2009. PMID: 19906354 No abstract available.
Similar articles
-
Easing the burden of treatment-resistant depression.J Clin Psychiatry. 2009 Feb;70(2):273-80. J Clin Psychiatry. 2009. PMID: 19265643 No abstract available.
-
Is baseline medication resistance associated with potential for relapse after successful remission of a depressive episode with ECT? Data from the Consortium for Research on Electroconvulsive Therapy (CORE).J Clin Psychiatry. 2009 Feb;70(2):232-7. doi: 10.4088/jcp.08m04092. Epub 2009 Jan 13. J Clin Psychiatry. 2009. PMID: 19192459 Clinical Trial.
-
Virchow-Robin space dilatation may predict resistance to antidepressant monotherapy in elderly patients with depression.J Affect Disord. 2007 Jan;97(1-3):265-70. doi: 10.1016/j.jad.2006.06.024. Epub 2006 Aug 17. J Affect Disord. 2007. PMID: 16919335
-
Diagnosis and definition of treatment-resistant depression.Biol Psychiatry. 2003 Apr 15;53(8):649-59. doi: 10.1016/s0006-3223(03)00231-2. Biol Psychiatry. 2003. PMID: 12706951 Review.
-
Novel Augmentation Strategies in Major Depression.Dan Med J. 2017 Apr;64(4):B5338. Dan Med J. 2017. PMID: 28385173 Review.
Cited by
-
Protocol for a randomised controlled trial of ketamine versus ketamine and behavioural activation therapy for adults with treatment-resistant depression in the community.BMJ Open. 2024 May 1;14(5):e084844. doi: 10.1136/bmjopen-2024-084844. BMJ Open. 2024. PMID: 38692731 Free PMC article. Clinical Trial.
-
Schema therapy versus treatment as usual for outpatients with difficult-to-treat depression: study protocol for a parallel group randomized clinical trial (DEPRE-ST).Trials. 2024 Apr 16;25(1):266. doi: 10.1186/s13063-024-08079-9. Trials. 2024. PMID: 38627837 Free PMC article.
-
Opportunities and challenges for the use of deep brain stimulation in the treatment of refractory major depression.Discov Ment Health. 2024 Mar 14;4(1):9. doi: 10.1007/s44192-024-00062-9. Discov Ment Health. 2024. PMID: 38483709 Free PMC article. Review.
-
Treating Treatment-resistant Depression with Esketamine Nasal Spray When All Therapeutic Options Have Been Exhausted: Clinical Experience from a Spanish Cohort of Expanded Use.Clin Psychopharmacol Neurosci. 2024 Feb 29;22(1):159-168. doi: 10.9758/cpn.23.1097. Epub 2023 Sep 6. Clin Psychopharmacol Neurosci. 2024. PMID: 38247422 Free PMC article.
-
The definition of treatment resistance in anxiety disorders: a Delphi method-based consensus guideline.World Psychiatry. 2024 Feb;23(1):113-123. doi: 10.1002/wps.21177. World Psychiatry. 2024. PMID: 38214637 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical